Navigation Links
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Date:12/8/2009

T: 206.282.7100 Lindsey Jesch T: 206.272.4347 F: 206.272.4434 E: invest@ctiseattle.com www.CellTherapeutics.com/investors Medical Information Contact: T: 800.715.0944 E: info@askarm.com

SOURCE Cell Therapeutics, Inc.


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
4. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
5. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
9. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 2013  Recent regulatory and budget challenges have made ... at large pharmaceutical companies to effectively educate doctors and ... of their new products. With the pressure to reduce ... that these "Med Ed" groups find practical, ... address the changes that are transforming the Medical Education ...
(Date:6/18/2013)... , June 18, 2013 Unilife Corporation ... based designer, developer and manufacturer of injectable drug delivery ... website at www.unilife.com . The new site includes ... updates to occur on a regular basis. ... stated, "As an emerging global leader for injectable drug ...
(Date:6/18/2013)... , June 18, 2013  Specialty ... significant breakthrough in Parylene coating technologies: SCS ... the benefits of Parylene with antimicrobial properties ... devices and components. (Logo: ... infections (HAIs) increase and continue to pose ...
Breaking Medicine Technology:Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2Unilife Launches New Corporate Website 2Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2
... All pre-specified subset analyses of progression-free survival,in the ... in,relative risk of disease progression for patients receiving,satraplatin. ... as presence or absence of pain. -- The ... - radiologic,progression and pain progression - were each ...
... ,Abstracts: 2000, 2002 , CHICAGO/DARMSTADT, Germany, June 4, ... today at the American Society of,Clinical Oncology (ASCO) ... cilengitide in patients with newly diagnosed,glioblastoma – a ... highly selective integrin inhibitor targeting the,tumor and its ...
Cached Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
(Date:6/19/2013)... 2013 At a Travel Services Member Conference, ... growth that has occurred over the last year since he ... said, "Travel Services has added vendors, lowered prices of travel ... Membership is up, even in the tough economy, and they've ... members." , Having been in the Travel Business and Timeshare ...
(Date:6/19/2013)... The motor neuron disease Amyotrophic lateral sclerosis (ALS), also ... sequential pattern which can be classified into four distinct ... at the University of Pennsylvania in the Annals ... and spinal cord tissues shows, for the first time, ... starting point in the central nervous system to other ...
(Date:6/19/2013)... from a naturally occurring compound (apocynin), has been ... Parkinson,s Disease symptoms by preventing deficits in motor ... May 28, 2013 edition of Neuroscience ... fellow at the Medical College of Wisconsin (MCW), ... Balaraman Kalyanaraman, Ph.D., Harry R. & Angeline E. ...
(Date:6/19/2013)... Imprivata ®, a leading global provider ... Imprivata OneSign ® leads the single sign-on (SSO) category ... & Services report . CIOs and other healthcare executives ... performance of its products and the quality of its ... is integral to their long-term healthcare IT strategy. ...
(Date:6/19/2013)... 19, 2013 The US Food and Drug ... ultra cohesive gel breast implant, Mentor Worldwide’s MemoryShape™. , The ... February 2013. The FDA announced the approval of the MemoryShape™ ... primary augmentations in women 22 years old or ... , The FDA’s approval comes after six years of ...
Breaking Medicine News(10 mins):Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3Health News:FDA Approved Mentor® MemoryShape™ Breast Implants Now Offered to Patients at Swan Center for Plastic Surgery 2
... between the ages of 40 and 59 could substantially reduce ... the September 9 online issue of the Journal of ... are regularly used in developed countries where the incidence of ... is in place. The value and practicality of such screening ...
... ARBOR, Mich.---Pregnant women who take high levels of daily calcium ... blood, suggesting calcium could play a critical role in reducing ... University of Michigan shows that women who take 1,200 milligrams ... in lead levels. , Women who used lead-glazed ceramics and ...
... still giving them to new moms , , TUESDAY, Sept. ... the majority of East Coast hospitals report giving formula ... medical organizations oppose this practice. , The study, ... of Pediatrics & Adolescent Medicine , surveyed 1,295 ...
... Physician Recruitment Firm Will Grow Through Leadership Development and ... ... Alpharetta, Ga. (Vocus) September 9, 2008 -- ... Jackson president of Alpharetta, Ga.-based http://www.locumtenens.com/new_leader08 [LocumTenens.com]. ...
... that sugar,makes good foods taste better, helps breads rise, ... jams and jellies. But,did you know the same preserving ... heal wounds?, Sugar is one of Mother Nature,s ... sugar an excellent food preservative also bestow,it with its ...
... may be better able to comply with medication regimens ... tables that track what they take and when they ... "medtable" may help to prevent medication-related problems. A report ... Experimental Psychology: Applied, published by the American ...
Cached Medicine News:Health News:Breast cancer screening may lower mortality and disease burden in India 2Health News:Calcium during pregnancy reduces harmful blood lead levels 2Health News:Formula Samples Hinder Breast-Feeding Efforts 2Health News:R. Shane Jackson Named President of LocumTenens.com 2Health News:R. Shane Jackson Named President of LocumTenens.com 3Health News:Sugar's Healing Powers 2Health News:Older adults can take medicines more safely and effectively by charting their daily routines 2Health News:Older adults can take medicines more safely and effectively by charting their daily routines 3
... a 60 watt diode continuous wave laser with ... Power Bar technology and 940 nm wavelength make ... for varicose veins and a variety of surgical ... safety features including the LPS, Light guide Protection ...
... is an instrument and LIS independent connectivity ... to work more efficiently than ever. It ... solution that stands between instrument or medical ... important gaps in functionality between the two, ...
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... the Farnsworth 100 Hue Test comes boxed in ... reduces the potential for test disruption by ... 100 Hue test from Richmond Products includes 93 ... a durable laminated score template for copying, a ...
Medicine Products: